abstract |
The present invention relates to diazine and triazine compounds having activity as Interleukin inhibitors, particularly Interleukinâ1 beta, 2, 4, 6, 8, 13 and 17, and to the compounds for use in the treatment of associated disorders, particularly Alzheimer's Disease, Parkinson's Disease, Asthma, and solid organ transplant rejection. |